From 1 January 2021 the UK will no longer be part of EU IP systems. UK intellectual property rights will now co-exist alongside EU and national IP systems in Europe and the European Union.
As a European firm, HGF will continue to advise and to act for our clients in all aspects of patents, trade marks and designs across Europe. HGF will work with our clients to put in place strategies to address the changing IP landscape in Europe.
The headline points to note in respect of IP rights post-Brexit are that:
HGF continue to represent clients for all matters before the EPO and EUIPO in respect of European IP rights, as well as before national IP offices where we operate.
If you have any questions or concerns about IP Rights, or would like further advice on this matter, please contact your usual HGF attorney.
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
We are delighted to launch our new Fashionably IP Podcast were we will be looking at important hot topics in the world of fashion and intellectual property. In the podcast, …Read article
The Court of Appeal has stayed an interim injunction to allow Mylan’s generic to remain on the market in a bid to preserve the status quo, despite recognising that damages …Read article
After months of research, Managing IP has published the IP Stars list for 2022. HGF is delighted to have 16 attorneys from England, Scotland, Ireland, Netherlands and Germany recognised and …Read article
We are delighted to announce that HGF is shortlisted for 11 awards at the upcoming Managing IP EMEA Awards 2022: European European Firm of the Year – Patent Contentious (Patent …Read article
We are excited to mark and celebrate our 3-year partnership with award winning charity In2Science UK. Our partnership has gone from strength to strength, and we are delighted to confirm …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
The UK musician, Ed Sheeran, one of the world’s best selling artists with sales of 26 million albums and 100 million singles worldwide, has successfully defended a claim brought against …Read article